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Abstract
The female genital mucosa constitutes the major port of entry of sexually transmitted infections. Most genital microbial pathogens rep-
resent an enormous challenge for developing vaccines that can induce genital immunity that will prevent their transmission. It is now
established that long-lasting protective immunity at mucosal surfaces has to involve local B-cell and T-cell effectors as well as local mem-
ory cells. Mucosal immunization constitutes an attractive way to generate systemic and genital B-cell and T-cell immune responses that
can control early infection by sexually transmitted pathogens. Nevertheless, no mucosal vaccines against sexually transmitted infections
are approved for human use. The mucosa-associated immune system is highly compartmentalized and the selection of any particular
route or combinations of routes of immunization is critical when defining vaccine strategies against genital infections. Furthermore,
mucosal surfaces are complex immunocompetent tissues that comprise antigen-presenting cells and also innate immune effectors and
non-immune cells that can act as ‘natural adjuvants’ or negative immune modulators. The functions of these cells have to be taken into
account when designing tissue-specific antigen-delivery systems and adjuvants. Here, we will discuss data that compare different mucosal
routes of immunization to generate B-cell and T-cell responses in the genital tract, with a special emphasis on the newly described sub-
lingual route of immunization. We will also summarize data on the understanding of the effector and induction mechanisms of genital
immunity that may influence the development of vaccine strategies against genital infections.
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Introduction
The female genital tract consists of the upper reproductive
tract (uterus and cervix) and the lower reproductive tract
(vagina). It constitutes the major port of entry of several
pathogens such as human immunodeficiency virus (HIV),
herpes simplex virus (HSV), human papillomavirus, Chlamydia
and Neisseria gonorrhoeae. These sexually transmitted
infections (STI) represent a major public health problem in
both industrialized and developing countries. Hence, develop-
ment of vaccines that can induce a strong genital immunity pre-
venting STI transmission is crucial but challenging. Indeed,
despite numerous efforts, the sole human vaccines licensed to
prevent an STI until now are the human papillomavirus vac-
cines Gardasil and Cervarix. These prophylactic vaccines
that are given by intramuscular injection are believed to confer
protection by inducing genital neutralizing antibodies derived
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from the circulation [1–3]. For other pathogens, in particular
HIV and HSV-2, a protective immunity has to elicit strong B-
cell and T-cell responses both at the site of infection and in the
periphery to block systemic spreading [4–6]. Ideally, a vaccine
against genital infection should induce genital and systemic
immune responses involving effector B-cell, CD4 and CD8 T-
cell responses as well as local B and T memory cells.
The mucosa-associated immune system is highly compart-
mentalized. Mucosal immunization, unlike parenteral immuni-
zation, is able to favour the generation of secretory
antibodies (IgA) and CD4 and CD8 T cells both at the site
of mucosal immunization and in distant mucosae under cer-
tain conditions [7,8]. Interestingly, Gallichan and Rosenthal
demonstrated that mucosal immunization generates mucosal
long-term CD8 T cells, in contrast to parenteral immuniza-
tion, and that these tissue-associated memory T cells are
critical for antiviral protection against mucosal challenge [9].
Hence, characterizing the phenotype of long-term tissue-
associated effector immune cells in the genital mucosa and
identifying the cellular and molecular mechanisms that induce
their generation and their specific homing in the genital tract
are of particular interest for development of vaccines against
STI. Moreover, the generation of efficient mucosal and sys-
temic immune responses following mucosal immunization
requires the use of appropriate adjuvants and antigen-deliv-
ery systems [10–12]. These vaccine components will influ-
ence the quality and the nature of the immunity needed at a
desired site of the body.
Therefore, the design of vaccines against STI must take
into account the routes of immunization as well as the nat-
ure of the components of the vaccines themselves. A major
question to be answered is where and how a vaccine against
an STI has to be delivered to generate a robust and tissue-
specific long-lasting immunity in the female genital tract. In
this review, we will summarize data that compare different
mucosal routes of immunization to generate B-cell and T-cell
responses in the genital tract, with a special emphasis on the
newly described sublingual route of immunization. We will
also discuss data available on effector and induction mecha-
nisms of mucosal immunity that may influence the develop-
ment of vaccine strategies against genital infections.
Routes of Immunization and B-cell and
T-cell Immunity in the Female Genital Tract
Comparison of mucosal and parenteral routes of
immunization
Numerous studies have compared the potential of different
mucosal routes of immunization to generate IgG and IgA
antibody responses in the human and mouse cervico-vaginal
mucosae after topical application of non-replicating vaccines
as reviewed elsewhere [11]. Vaginal immunization was shown
to induce IgA and IgG antibody-secreting cells in vagina and
uterus as well as cervico-vaginal and seric antibodies [13–
15]. Furthermore, nasal immunization gave rise to IgA and
IgG antibody responses in human cervico-vaginal washes with
intensities comparable to those seen following vaginal immu-
nization [14]. Several studies comparing different routes of
immunization with replicating or non-replicating model anti-
gens in mice have also documented that nasal immunization
can induce IgA and IgG antibodies as well as effector T cells
in the genital tract [15–17]. The potential of the sublingual
route for delivering vaccines has gained interest because it
favours the induction of broadly disseminated mucosal and
systemic immune responses [18,19]. Notably, sublingual
immunization was as potent as vaginal immunization for the
induction of IgA and IgG antibodies and cytotoxic T cells in
the female genital tract, in contrast to parenteral immuniza-
tion [15,20]. Furthermore, sublingual immunization with
human papillomavirus-like particles evoked virus-neutralizing
antibody responses in both serum and cervico-vaginal
washes, and provided protection against genital challenge
with human papillomavirus pseudovirions [15]. In addition,
sublingual immunization of female macaques with an HIV sub-
unit vaccine induced IgG and IgA antibody responses in the
genital tract (F. Anjue`re, unpublished results). It should also
be noted that the sublingual route of immunization reduces
the risk that antigens and adjuvants are redirected to the
olfactory bulb epithelium, as observed after intranasal vacci-
nation. Altogether, these studies suggest that this novel
route of immunization may constitute an interesting alterna-
tive route to intranasal immunization for human vaccination
against urogenital infections.
Combination of routes of immunization
Recent studies indicated that a prime-boost strategy com-
prising a mucosal prime followed by an intramuscular boost
immunization was beneficial to generate protective immunity
either in macaques against a challenge by simian HIV [21] or
in mice against Chlamydia genital shedding [22]. In both stud-
ies, the mucosal immunization (intranasal or sublingual) was
able to induce a protective immunity in combination with an
intramuscular immunization whereas parenteral immunization
alone was not. Another recent study in mice highlighted that
a local vaginal boost immunization after a nasal prime is even
superior to intranasal boost to induce protection against
Chlamydia infection [23]. Furthermore, vaginal prime/boost
strategy using two recombinant vectors was more efficient
than other routes of immunization (systemic and mucosal) to
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induce a protective immunity against a genital challenge with
a recombinant vaccinia virus [24]. In these studies, local
immunization was shown to favour the amplification and
maintenance of long-lived tissue-resident CD4 and CD8
T cells that play a central role in protection against most
genital pathogens.
Generation of memory responses in the female genital tract
Recent studies showed that cutaneous and intravaginal viral
infections in mice induce the generation of high-affinity tissue-
resident CD8 memory T cells that are critical for the control
of epithelial pathogens re-encountered at their port of entry
[25,26]. Interestingly, Gallichan and Rosenthal demonstrated
that mucosal immunization generates mucosal long-term CD8
T cells in contrast to parenteral immunization and, that these
T cells were critical for antiviral protection against a mucosal
challenge [9]. Hence, the generation of tissue-resident mem-
ory T cells must be a goal of vaccination as reviewed else-
where [27]. A question that arises is whether replication-
defective vaccines can be as efficient as pathogens themselves
or as live vaccines to generate these cells? As a non-replicat-
ing Chlamydia vaccine was able to generate long-term protec-
tive CD4 T cells in the genital tract, this suggests that it is
feasible [23]. The next steps toward the development of vac-
cines generating memory T cells in the genital tract will be to
further characterize these cells and to identify the local fac-
tors that favour their vaginal expansion and maintenance.
Adjuvants
The adjuvants, the antigen-delivery systems and the vaccine
formulations employed will have profound influences on the
intensity and the nature of mucosal immune responses
generated. Potent immunomodulatory agents, including
toxin-based adjuvants, Toll-like receptor mimetics and non-
Toll-like receptor-targeting immunostimulators as well as
delivery systems are under evaluation in animal models and
may represent components of future vaccines as extensively
detailed elsewhere [11,12,28,29]. Such immune modulators
will be useful for the development of vaccines against genital
infections if they can improve the development of vagina-
associated memory B and T cells.
Homing of Effector Cells in the Female
Genital Tract
The homing of lymphocytes to specific tissues is a key com-
ponent of mucosal immunity and is under the control of
chemokine receptors and integrins expressed by effector
cells as well as addressins and chemokines expressed in
tissues. It is already well known that the selective expression
of the integrin a4b7 and the chemokine receptor CCR9
by effector B and T cells determines their homing to gut-
associated lymphoid tissue [30,31]. In contrast, the homing
phenotype of B and T effector and memory cells to the
female genital mucosa is partially understood. Recent data
indicated that the chemokine receptor CCR10 plays a role
in the migration of IgA-producing plasma cells to the genital
tissue in response to the chemokine CCL28 by a mechanism
that is dependent on oestrogens [15,32]. Both studies also
demonstrated that the IgA-specific CCR10+ plasma cells pro-
duced by sublingual and nasal immunizations preferentially
migrate to the uterine mucosa [15,32]. Furthermore, the
expression of the aE integrin (CD103) by cervical human
gag-specific CD8 T cells [33] and by genital HSV-specific
memory T cells [26] suggested that CD103 expression is
important for the mucosal homing and for the maintenance
of T cells in the female genital tract. A question that then
arises is what are the cellular and molecular mechanisms
involved in the homing and the retention of effector and
memory cells in the female genital tract.
Role of Dendritic Cells in the Generation of
Genital Effectors
Dendritic cells (DCs) represent professional antigen-present-
ing cells that have dual roles: the initiation of productive
adaptive immunity including the generation of anti-tumour
cytotoxic T cells and the induction of immunoregulation
through the differentiation of regulatory T-cell subsets. The
vaginal mucosa comprises distinct subsets of DCs including
intra-epithelial DCs expressing or not the langerin marker,
as well as submucosal DCs [34,35]. The presentation of non-
replicating antigens or pathogens following vaginal immuniza-
tion was shown to mainly involve DCs able to locally take
up and process the antigen, and to carry it to draining lymph
nodes to prime naive CD4 and CD8 T cells [6]. We and
others have demonstrated that the mucosal administration of
a protein antigen with cholera toxin used as adjuvant induces
the transient recruitment of immunostimulatory DCs at the
site of immunization, which triggers the generation of sys-
temic and mucosal CD8+ effector T cells [36–38]. Interest-
ingly, a subset of CD11b+ DCs recruited in the vagina after
local stimulation played a crucial role in the generation of
vaginal cytotoxic CD8 T-cell responses whereas langerin-
expressing DCs dampened these responses [35]. Vaginal sub-
mucosal CD11b+ DCs were also involved in the presentation
of HSV-derived antigens to CD4 T cells following HSV-2
intravaginal infection [39]. These data indicate that submuco-
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sal CD11b+ DCs, but not Langerhans cells, may constitute
a potential target for vaccines that aim to generate protec-
tive genital CD4 and CD8 T cells. This would require the
identification of an appropriate surface marker restricted to
this particular DC subset. Vaginal submucosal DCs share the
ability to cross-present exogenous antigens with dermal
XCR1+ CD103+ DCs, which indicates that, if expressed on
mucosal CD11b+ DCs, these markers might be useful to
develop specific DC-targeted vaccines [38,40]. Nevertheless,
further studies are needed to identify markers restricted to
submucosal CD11b+ DCs. Furthermore, tissue-associated
DCs were reported to produce factors that can influence
the expression of mucosal homing markers by activated T
and B cells. This has been well documented in the gastroin-
testinal tract, where a specific CD103+ DC subset that
metabolizes retinoic acid induced the expression of the inte-
grin a4b7 and the chemokine CCR9 on activated T cells and
on antibody-secreting cells, so favouring their migration to
gut-associated lymphoid tissue [30,41]. This discovery may
have implications in the field of mucosal immunization
because DCs from non-intestinal epithelial sites do not
produce retinoic acid. Interestingly, it was recently shown
that adding retinoic acid to a vaccine preparation was suffi-
cient to induce the migration of CD8 effector T cells to the
vaginal mucosa and to protect mice against a genital chal-
lenge with HSV [42], indicating that retinoic acid might be a
component of vaccines that aim to elicit genital immunity.
Consequently, as vaginal CD11b+ DCs induce the homing
of T-cell effectors to the vaginal mucosa, one can ask
whether and how these DCs can imprint vaginal T cells and
whether one can identify a surface marker selectively
expressed by this DC subset to develop a DC-targeted vac-
cine against genital infections.
Mucosal Innate Effector Cells as Immune
Modulators of Genital B-cell and T-cell
Immunity
Different subsets of innate cells are present or recruited to
mucosae following inflammatory processes and infections
where they play a major role in innate defense. Natural killer
(NK) cells are cytotoxic lymphocytes of the innate immune
system [43,44], and are potent immune modulators of adap-
tive immunity during infections either by exerting their cyto-
lytic activity on effector and central memory T lymphocytes
[45–48], or by killing antigen-presenting DCs [49]. Further-
more, NK cells have been recently identified in sub-epithelial
tissues (skin, intestine, tonsils) in humans and mice [50–52],
but they remain to be fully characterized in the female genital
tract. Nevertheless, the contribution of NK cells in protection
against intravaginal HSV-2 infection was evaluated using animal
models where the differentiation of NK cells is affected.
These studies suggested that NK cells are crucial for the viral
clearance even if the models used did not specifically deplete
NK cells [53,54]. Further experiments are needed to evaluate
the role of NK cells in vaginal antiviral immunity. Further-
more, a question that also arises is whether vaginal NK cells
can modulate genital T-cell and B-cell immunity and how?
Recently, interleukin-6-producing NK cells characterized in
the lymph nodes draining the nasal mucosa were shown to
potentiate the induction of mucosal antibodies after nasal
immunization, showing that mucosa-derived NK cells can con-
tribute to the generation of mucosal adaptive immunity [55].
Different subsets of NK T lymphocytes have been mainly
studied in the skin. They have also been recently identified in
the intestinal mucosa [56] but their presence and role in plu-
ristratified mucosae remain to be established. Nevertheless,
the nasal administration of the aGalCer molecule as mucosal
adjuvant together with an HSV antigen was shown to
increase the generation of HSV-specific effector T cells and
to improve the protection of mice against a genital challenge
by HSV-2 [57]. This study suggests that the activation of
mucosal NKT cells by aGalCer ligand potentiates adaptive
immune responses induced by mucosal immunization.
Further characterization of NK and NKT cells present in
the vaginal mucosa and other mucosal sites of induction of
genital immunity (nasal and sublingual mucosae) is needed to
elucidate their functional properties during mucosal vaccina-
tion, as well as their impact on genital effector responses. A
better understanding of the functions of these innate cells
following mucosal immunization may help to optimize vac-
cines strategies against STI.
Conclusions
Recent data highlighted that mucosal immunization or combi-
nations of mucosal and parenteral immunizations are crucial
for the generation of protective immunity against different
genital pathogens, probably because these vaccine strategies
favour the expansion of long-lasting B-cell and T-cell
responses in the genital tract. Future research should be ded-
icated to a better understanding of mechanisms of induction
of genital B-cell and T-cell immunity. Particular attention
should be paid to the role of tissue-associated dendritic cell
subsets and to the emerging role of mucosa-associated innate
immune cells in the generation of protective immunity, as
well as to the mechanisms of homing and retention of cervi-
co-vaginal memory cells which are critical for protection.
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